Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator

被引:80
|
作者
Nighoghossian, N
Hermier, M
Adeleine, P
Derex, L
Dugor, JF
Philippeau, F
Ylmaz, H
Honnorat, J
Dardel, P
Berthezéne, Y
Froment, JC
Trouillas, P
机构
[1] Hop Neurol & Neurochirurg P Wertheimer, Biostat Unit, F-69003 Lyon, France
[2] CNRS, Cerebrovasc Dis Ctr, F-75700 Paris, France
[3] CNRS, Dept Radiol, F-75700 Paris, France
[4] CNRS, Creatis UMR 5515, F-75700 Paris, France
关键词
magnetic resonance imaging; diffusion-weighted magnetic resonance imaging; perfusion-weighted; stroke outcome; tissue plasminogen activator;
D O I
10.1161/01.STR.0000053850.64877.AF
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We designed a prospective sequential pretreatment and posttreatment MRI study to assess the relation between neuroimaging parameters and clinical outcome in patients treated with intravenous recombinant tissue-type plasminogen activator (rtPA). Methods-Patients with symptoms of acute hemispheric ischemic stroke were recruited. The National Institutes of Health Stroke Scale (NIHSS) score was assessed at baseline and at days 1, 7, and 60, and the modified Rankin scale (mRS) at day 60, by which outcome was classified in terms of independence (mRS score 0, 1, or 2) or severe disability or death (mRS score 3 through 6), was assigned. Multimodal stroke MRI was performed at presentation and repeated at day 1. MRI procedures included magnetic resonance angiography, T2* gradient-echo sequence, echoplanar imaging, and isotropic diffusion- (DWI) and perfusion-weighted (PWI) imaging. Patients were treated with intravenous rtPA after MRI completion. Results-Twenty-nine patients (16 men and 13 women; mean+/-SD age, 65+/-14 years) underwent MRI; the mean time from symptom onset to treatment was 255 62 minutes. Twenty-six patients had a vessel occlusion, and 15 patients experienced a partial (Thrombolysis in Myocardial Infarction [TIMI]-2) or total (TIMI-3) recanalization at day 1, whereas 11 patients had a persistent occlusion. Mean NIHSS scores at day 60 were 5.7+/-5.4 if recanalization had occurred and 14+/-2 in cases of persistent occlusion. According to the mRS, 13 patients were independent (mRS 0 through 2), whereas severe disability or death (mRS 3 through 6) was observed in 15 patients. A better outcome was observed when recanalization was achieved (r= -0.68, P=0.0002). PWI volume and time to peak (TTP) within the DWI lesion assessed before therapy were correlated with day-60 NIHSS score (PWI volume: r=0.51, P=0.006, TTP: r=0.35, P=0.07). The day-0 DWI abnormality volume was well correlated with day-60 NIHSS score (r=0.58, P=0.001). Multiple regression linear analysis showed that 2 factors mainly influenced clinical outcome: (1) recanalization, with a high correlation with NIHSS score at day 60 (P=0.0001) and (2) day-0 DWI lesion volume, which is closely associated with day-60 NIHSS score (P=0.03). Conclusions-Baseline DWI volume and recanalization are the main factors influencing clinical outcome after rtPA for ischemic stroke.
引用
收藏
页码:458 / 463
页数:6
相关论文
共 50 条
  • [1] Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator
    Alexandrov, AV
    Grotta, JC
    [J]. NEUROLOGY, 2002, 59 (06) : 862 - 867
  • [2] Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator-Treated Patients
    Spokoyny, Ilana
    Raman, Rema
    Ernstrom, Karin
    Meyer, Brett C.
    Hemmen, Thomas M.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (05): : 1046 - 1050
  • [3] Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator
    Derex, L
    Hermier, M
    Adeleine, P
    Pialat, JB
    Wiart, M
    Berthezène, Y
    Philippeau, F
    Honnorat, J
    Froment, JC
    Trouillas, P
    Nighoghossian, N
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (01): : 70 - 75
  • [4] In-hospital stroke treated with intravenous tissue plasminogen activator
    Masjuan, Jaime
    Simal, Patricia
    Fuentes, Blanca
    Antonio Egido, Jose
    Diaz-Otero, Fernando
    Gil-Nunez, Antonio
    Elena Novillo-Lopez, Maria
    Diez-Tejedor, Exuperio
    Alonso de Lecinana, Maria
    [J]. STROKE, 2008, 39 (09) : 2614 - 2616
  • [5] Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator
    Derex, L
    Nighoghossian, N
    Hermier, M
    Adeleine, P
    Berthezène, Y
    Philippeau, F
    Honnorat, K
    Froment, JC
    Trouillas, P
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 225 (1-2) : 3 - 9
  • [6] Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients
    Takeuchi, Satoru
    Wada, Kojiro
    Nagatani, Kimihiro
    Otani, Naoki
    Osada, Hideo
    Nawashiro, Hiroshi
    [J]. ACTA NEUROCHIRURGICA, 2012, 154 (01) : 87 - 87
  • [7] Development of orolingual angioedema in ischemic stroke patients treated with intravenous tissue plasminogen activator
    Khaja, Aslam M.
    Merrick, Michael T.
    Noser, Elizabeth A.
    Albright, Karen C.
    Gonzales, Nicole R.
    Barreto, Andrew D.
    Martin-Schild, Sheryl
    Hallevi, Hen
    Illoh, Kachikwu
    Shaltoni, Hashem M.
    Grotta, James C.
    [J]. STROKE, 2007, 38 (02) : 506 - 506
  • [8] Very Early Mobilization in Stroke Patients Treated with Intravenous Recombinant Tissue Plasminogen Activator
    Arnold, Scott M.
    Dinkins, Maryane
    Mooney, Lesia H.
    Freeman, William D.
    Rawal, Bhupendra
    Heckman, Michael G.
    Davis, Olivia A.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (06): : 1168 - 1173
  • [9] Seasonal difference in the incidence of ischemic stroke patients treated with intravenous tissue plasminogen activator
    Kodera, Y.
    Yutani, S.
    Mizuma, A.
    Uesugi, T.
    Tokuoka, K.
    Ohnuki, Y.
    Nagata, E.
    Takahashi, W.
    Takizawa, S.
    Kitagawa, Y.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2014, 9 : 67 - 67
  • [10] Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients
    Satoru Takeuchi
    Kojiro Wada
    Kimihiro Nagatani
    Naoki Otani
    Hideo Osada
    Hiroshi Nawashiro
    [J]. Acta Neurochirurgica, 2012, 154 : 87 - 87